913 North Market Street
Tel: 973-442-1555 ext. 116
48 articles with NeuroRx, Inc.
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
Observations of rapid recovery noted on chest x-ray and no drug-related Serious Adverse Events reported
NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020
NeuroRx, Inc. and Relief Therapeutics Holdings AG announced that the independent Data Monitoring Committee met yesterday and voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients.
NeuroRx Receives Notice of Allowance from USPTO for a Formulation for the Treatment of Post-Traumatic Stress Disorder
NeuroRx, Inc. today announced that it has received a notice of patent allowance from the United States Patent and Trademark Office (USPTO) covering a formulation for the treatment of post-traumatic stress disorder (PTSD), a condition according to the NIH that affects annually 3.6% or about 10-13 million people in the United States a
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Relief Therapeutics and NeuroRx released results on Tuesday from their open-label prospective study looking into RLF-100 (aviptadil) as a potential treatment for COVID-19 and respiratory failure.
NeuroRx's Dr. Jonathan Javitt to Present Company Overview at 2020 Solebury Trout Private Company Showcase
NeuroRx, Inc., a clinical-stage pharmaceutical company developing small molecules for unmet medical needs, announced that Chairman and CEO Jonathan C.
NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19
RLF-100™ therapy associated with a 9-fold increased probability of survival and recovery from respiratory failure in an open-label, prospective study
NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100™ (aviptadil)
Development partners establish supply chain agreements and order sufficient drug substance to treat 1 million patients
NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy
Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners
Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) has been reported under FDA Emergency Use IND authorization at multiple clinical sites
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung
RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells
Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites
FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19: Currently in development by NeuroRx and Relief Therapeutics under Fast Track Designation
Expanded access is available to patients who are ineligible for enrollment in the FDA clinical trial of RLF-100, including pregnant women
7/20/2020It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19
NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holdings AG announced that the independent Data Monitoring Committee has reviewed the findings in the first 30 patients treated in Fast Track FDA trials of RLF-100 in patients with Critical COVID-19 with respiratory failure.
6/29/2020It was a busy week for clinical trial updates. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.